MX2017015801A - Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas. - Google Patents

Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.

Info

Publication number
MX2017015801A
MX2017015801A MX2017015801A MX2017015801A MX2017015801A MX 2017015801 A MX2017015801 A MX 2017015801A MX 2017015801 A MX2017015801 A MX 2017015801A MX 2017015801 A MX2017015801 A MX 2017015801A MX 2017015801 A MX2017015801 A MX 2017015801A
Authority
MX
Mexico
Prior art keywords
affinity
binding domain
tcr
same
antibody binding
Prior art date
Application number
MX2017015801A
Other languages
English (en)
Inventor
Peled Kamar Mira
Denkberg Galit
Reiter Yoram
Beer Ilan
Sinik Keren
Shperber Yael (Sery)
Erel Segal Reut
Oren Ravit
Shmuel ALISHEKEVITZ Dror
Teboul Yael (Elbaz)
Original Assignee
Adicet Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adicet Bio Inc filed Critical Adicet Bio Inc
Publication of MX2017015801A publication Critical patent/MX2017015801A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan entidades de unión de afinidad que tienen un dominio de unión a TCRL y procedimientos para su uso. Más específicamente, estas composiciones se unen a células HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAE-A9, HLA-A2/PAP o HLA-A2/TyrD+ y, como tal, pueden usarse en diagnóstico y terapia.
MX2017015801A 2015-06-08 2016-06-08 Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas. MX2017015801A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562172264P 2015-06-08 2015-06-08
NL2014935A NL2014935B1 (en) 2015-06-08 2015-06-08 T cell receptor like antibodies having fine specificity.
PCT/IL2016/050600 WO2016199141A2 (en) 2015-06-08 2016-06-08 Affinity entities comprising a tcr-like antibody binding domain with high affinity and fine specificity and uses of same

Publications (1)

Publication Number Publication Date
MX2017015801A true MX2017015801A (es) 2018-08-01

Family

ID=54325627

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017015928A MX2017015928A (es) 2015-06-08 2016-06-08 Anticuerpos similares al receptor de celulas t que tienen una especificidad fina.
MX2017015801A MX2017015801A (es) 2015-06-08 2016-06-08 Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.
MX2022009493A MX2022009493A (es) 2015-06-08 2017-12-06 Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017015928A MX2017015928A (es) 2015-06-08 2016-06-08 Anticuerpos similares al receptor de celulas t que tienen una especificidad fina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022009493A MX2022009493A (es) 2015-06-08 2017-12-06 Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.

Country Status (13)

Country Link
US (2) US11001642B2 (es)
EP (3) EP3302537A1 (es)
JP (5) JP6912392B2 (es)
KR (2) KR20180012851A (es)
CN (4) CN108025045B (es)
AU (3) AU2016276555B2 (es)
CA (3) CA3220475A1 (es)
ES (1) ES2922236T3 (es)
IL (3) IL256178B2 (es)
MX (3) MX2017015928A (es)
NL (1) NL2014935B1 (es)
SG (1) SG10202007398PA (es)
WO (2) WO2016199141A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49157A (fr) 2014-12-23 2021-06-02 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
AU2016342041B2 (en) 2015-10-23 2021-12-02 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
WO2018140525A1 (en) * 2017-01-24 2018-08-02 Abexxa Biologics, Inc. Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancer
SG11201909541WA (en) 2017-04-26 2019-11-28 Eureka Therapeutics Inc Chimeric antibody/t-cell receptor constructs and uses thereof
EP3635000A4 (en) * 2017-05-16 2021-04-14 The Johns Hopkins University MANABODIES AND METHODS OF USE
CA3065402A1 (en) * 2017-05-31 2018-12-06 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy
WO2018225732A1 (ja) * 2017-06-05 2018-12-13 国立大学法人三重大学 Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質
AU2017418590A1 (en) * 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
BR112020011469A2 (pt) * 2017-12-21 2020-11-24 F. Hoffmann-La Roche Ag anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
CN112351795A (zh) * 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
GB201803750D0 (en) * 2018-03-08 2018-04-25 Immunocore Ltd Method
AU2019283639A1 (en) * 2018-06-04 2021-01-07 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
JP7090204B2 (ja) * 2018-07-19 2022-06-23 イーライ リリー アンド カンパニー 免疫チェックポイントを標的とする二重特異性抗体
AU2019327490A1 (en) * 2018-08-30 2021-03-25 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
SG11202103234RA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS
WO2020072536A1 (en) 2018-10-01 2020-04-09 Adicet Bio, Inc. COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
KR20210134091A (ko) * 2019-01-29 2021-11-08 그릿스톤 바이오, 인코포레이티드 다중특이적 결합 단백질
SG11202109701SA (en) * 2019-03-25 2021-10-28 Univ Health Network T cell receptors and methods of use thereof
BR112021025548A2 (pt) * 2019-06-18 2022-05-17 Regeneron Pharma Receptores de células t mage-a4 e métodos de uso dos mesmos
CN114174345A (zh) * 2019-07-24 2022-03-11 瑞泽恩制药公司 具有mage-a4特异性的嵌合抗原受体和其用途
US20210048442A1 (en) 2019-08-13 2021-02-18 Immatics Biotechnologies Gmbh Method for the characterization of peptide:mhc binding polypeptides
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
CN110563804A (zh) * 2019-09-19 2019-12-13 河南省农业科学院 基于天然免疫库筛选识别氧氟沙星单链抗体的多肽序列及应用
NL2024375B1 (en) * 2019-12-04 2021-08-31 Apo T B V Methods and means for attracting immune effector cells to tumor cells.
MX2022007635A (es) * 2019-12-18 2022-07-19 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4.
CN115485303A (zh) 2020-05-05 2022-12-16 瑞泽恩制药公司 包含CD28ζ和CD3ζ的CAR
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
WO2022190007A1 (en) * 2021-03-09 2022-09-15 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries
IL308231A (en) * 2021-05-04 2024-01-01 Regeneron Pharma MAGE-44-specific chimeric antigen receptors and their uses
WO2023110788A1 (en) * 2021-12-14 2023-06-22 F. Hoffmann-La Roche Ag Treatment of cancer using a hla-a2/mage-a4 x cd3 bispecific antibody and a 4-1bb (cd137) agonist
WO2024056758A1 (en) * 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US8258260B2 (en) 1970-02-11 2012-09-04 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
WO1997015597A1 (en) 1995-10-25 1997-05-01 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20090062512A1 (en) 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070099182A1 (en) 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DE10313819A1 (de) 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7488793B2 (en) 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
JP4773434B2 (ja) 2004-05-19 2011-09-14 イムノコア リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
ATE430164T1 (de) 2004-05-26 2009-05-15 Immunocore Ltd Hochaffine telomerase-t-zellen-rezeptoren
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
SI1642905T1 (sl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
JP2008535826A (ja) 2005-04-01 2008-09-04 メディジーン リミテッド 高親和性ｈｉｖｔ細胞レセプター
EP1717245B1 (en) 2005-04-26 2011-06-08 Immatics Biotechnologies GmbH T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
EP1806359B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
WO2007053956A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
WO2007143104A2 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2144935A2 (en) * 2007-03-29 2010-01-20 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
EP2562182B1 (en) 2007-07-27 2015-10-07 Immatics Biotechnologies GmbH Novel immunogenic epitopes for immunotherapy
CN101765434B (zh) 2007-07-27 2014-12-17 伊玛提克斯生物技术有限公司 抗肿瘤相关肽及相关抗癌疫苗组合物
SI2660248T1 (sl) 2007-07-27 2015-10-30 Immatics Biotechnologies Gmbh Nova imunoterapija proti možganskim tumorjem
US20110105724A1 (en) 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
WO2009090651A2 (en) 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
EP2409155A1 (en) 2009-03-15 2012-01-25 Technion Research and Development Foundation, Ltd. Soluble hla complexes for use in disease diagnosis
JP2012521761A (ja) 2009-03-25 2012-09-20 アルター・バイオサイエンス・コーポレーション Ｈｉｖｖｐｒ−特異的ｔ細胞受容体
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
CN102812043A (zh) 2009-11-19 2012-12-05 新加坡国立大学 用于制备t细胞受体样单克隆抗体的方法及其用途
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EA201291133A1 (ru) * 2010-04-30 2013-04-30 Алексион Фармасьютикалз, Инк. Антитела, обладающие пониженной иммуногенностью в организме человека
WO2012091563A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
SG10201602159VA (en) 2011-02-11 2016-04-28 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
SG193956A1 (en) * 2011-04-01 2013-11-29 Sloan Kettering Inst Cancer T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
WO2013105856A1 (en) * 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
CA2934033A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Fc-enhanced anti-wt1/hla antibody
JP6553069B2 (ja) 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗ｗｔ１／ｈｌａ二重特異性抗体
RU2754041C2 (ru) 2015-04-03 2021-08-25 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида afp/мнс, и виды их использования
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
AU2017418590A1 (en) * 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof

Also Published As

Publication number Publication date
KR20180011275A (ko) 2018-01-31
US20210388111A1 (en) 2021-12-16
IL256178B1 (en) 2023-09-01
EP3302538B1 (en) 2022-02-09
JP7013243B2 (ja) 2022-01-31
IL256177A (en) 2018-02-28
EP4039270A9 (en) 2023-03-22
KR20180012851A (ko) 2018-02-06
WO2016199140A1 (en) 2016-12-15
JP2018527884A (ja) 2018-09-27
CA3220475A1 (en) 2016-12-15
JP2024016092A (ja) 2024-02-06
US20180171024A1 (en) 2018-06-21
IL256178A (en) 2018-02-28
AU2016276555B2 (en) 2022-07-21
EP3302538A2 (en) 2018-04-11
IL304821A (en) 2023-09-01
NL2014935A (en) 2016-12-12
AU2016276555A1 (en) 2018-01-18
CN108025045A (zh) 2018-05-11
AU2016276556B2 (en) 2022-08-11
EP4039270A1 (en) 2022-08-10
CN107847569A (zh) 2018-03-27
ES2922236T3 (es) 2022-09-12
WO2016199140A8 (en) 2016-12-29
MX2017015928A (es) 2018-06-22
JP2022188107A (ja) 2022-12-20
JP2021176861A (ja) 2021-11-11
NL2014935B1 (en) 2017-02-03
JP6912392B2 (ja) 2021-08-04
CN108025045B (zh) 2022-04-26
AU2016276556A1 (en) 2018-01-18
WO2016199141A3 (en) 2017-01-19
JP7147018B2 (ja) 2022-10-04
CA2987889A1 (en) 2016-12-15
CA2988270A1 (en) 2016-12-15
US11001642B2 (en) 2021-05-11
MX2022009493A (es) 2022-12-13
WO2016199141A8 (en) 2017-11-16
WO2016199141A2 (en) 2016-12-15
JP7376655B2 (ja) 2023-11-08
AU2022268398A1 (en) 2022-12-15
AU2016276556C1 (en) 2023-01-19
EP3302537A1 (en) 2018-04-11
CN114437217A (zh) 2022-05-06
SG10202007398PA (en) 2020-09-29
CN114605547A (zh) 2022-06-10
JP2018526970A (ja) 2018-09-20
IL256178B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
MX2022009493A (es) Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
PH12018502118A1 (en) Chimeric receptors to flt3 and methods of use thereof
PH12016501644A1 (en) Binding proteins and methods of use thereof
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2016017271A (es) Moleculas con especificidad para cd45 y cd79.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MA40408A (fr) Molécules ayant une spécificité pour cd79 et cd22
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
EP4324518A3 (en) Antibody molecules to tim-3 and uses thereof
EP3954710A3 (en) Antibodies to canine interleukin-4 receptor alpha
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
PH12021550120A1 (en) Chimeric receptors to steap1 and methods of use thereof
NZ702285A (en) Staphylococcal coagulase antigens and methods of their use
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2019007356A (es) Polipeptidos de union y metodos para fabricarlos.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2021000288A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.